VIJAYA2023-10-012023-12-31 VIJAYA2023-10-012023-12-31 VIJAYA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member VIJAYA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member VIJAYA2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 543350 VIJAYA NOTLISTED Vijaya Diagnostic Centre Limited Equity 2023-04-01 2024-03-31 2024-02-05 2024-01-23 INR Lakhs Third quarter 13:00:00 14:40:00 2024-02-05 2024-02-05 Not applicable Single segment Diagnostic Services 2023-10-01 2023-12-31 Unaudited Consolidated 1326916000.00 51100000.00 1378016000.00 159880000.00 0.00 0.00 230284000.00 60607000.00 145410000.00 413697000.00 1009878000.00 368138000.00 -20500000.00 347638000.00 92266000.00 -4640000.00 87626000.00 0.00 260012000.00 0.00 0.00 0.00 0.00 260012000.00 485000.00 260497000.00 258487000.00 1525000.00 258972000.00 1525000.00 102309000.00 1 2.53 2.52 0.00 0.00 2.53 2.52 1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ( the Company ) and its subsidiaries (the Company and its subsidiaries together referred to as the Group ) have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ( Ind AS ) prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 05 February 2024. The statutory auditors have carried out limited review of the above results for the quarter and year-to-date ended 31 December 2023. An unmodified report has been issued by them thereon. 3. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 Operating Segments . 4. The Group has charged depreciation on Property, Plant and Equipment based on Written Down Value (“WDV ) method upto 31 December 2022. With effect from 01 January 2023, the Company has changed its method of depreciation from WDV to SLM (Straight Line Method) based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets. Accordingly, the depreciation expense is lower and profit before tax is higher by Rs. 1,017.54 lakhs and Rs. 2,741.34 lakhs for the quarter and year-to-date ended 31 December 2023 respectively. There is no impact on account of such change to the depreciation provided upto 31 December 2022 under WDV method. 5. During the quarter and year-to-date ended 31 December 2023, the Company has issued 41,157 and 237,464 equity shares of face value of Re. 1 each respectively on exercise of employee stock options. 6. The Company has incurred an amount of Rs. 205 lakhs for the evaluation of various acquisitions towards financial, legal and tax due diligence and for market study on the diagnostic business in target geographies. These expenses have been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company. 7. On 21 December 2023, the Company has acquired 100% equity stake in PH Diagnostic Centre Private Limited (PH) for a cash consideration of Rs. 13,465.00 lakhs as per the terms and conditions of the Share Purchase Agreement entered between the Company and the sellers, and along with the repayment of existing debt of Rs.1,285.00 lakhs the total transaction value amounted to Rs.14,750.00 lakhs. Post completion of the aforesaid acquisition, PH Diagnostic Centre Private Limited has become wholly-owned subsidiary of the Company. Accordingly the above results include the results of subsidiary P H Diagnostic centre Private Limited with effect from 21 December 2023. 8. The wholly owned subsidiaries of the Comapny namely Doctorslab Medical Services Private Limited and Namrata Diagnostic Centre Private Limited, have applied for strike off to the Registrar of Companies (ROC), since there were no operations in these companies. There is no impact on account of this in the above results. 9. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 3926001000.00 175677000.00 4101678000.00 466240000.00 0.00 0.00 656969000.00 177957000.00 406989000.00 1224899000.00 2933054000.00 1168624000.00 -20500000.00 1148124000.00 249974000.00 38555000.00 288529000.00 0.00 859595000.00 0.00 0.00 0.00 0.00 859595000.00 1454000.00 861049000.00 853744000.00 5851000.00 855198000.00 5851000.00 102309000.00 1 8.35 8.33 0.00 0.00 8.35 8.33 Other Expenses 413697000.00 Other Expenses 1224899000.00 648000.00 1943000.00 163000.00 489000.00